Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
暂无分享,去创建一个
S. Yusuf | P. Pais | J. Pogue | R. Diaz | S. Connolly | S. Hohnloser | M. O’Donnell | J. Eikelboom | G. Flaker | C. Joyner | R. Hart | J. Lawrence | D. Synhorst
[1] Deepak L. Bhatt,et al. Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial , 2009, Circulation.
[2] Salim Yusuf,et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[3] J. Plumb,et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. , 2009, Thrombosis research.
[4] Timothy Watson,et al. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited , 2009, The Lancet.
[5] G. Karthikeyan,et al. New oral anticoagulants: not quite there yet. , 2009, Polskie Archiwum Medycyny Wewnetrznej.
[6] J. Ansell,et al. Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict , 2008 .
[7] S. Yusuf,et al. Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range , 2008, Circulation.
[8] R. de Caterina,et al. Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W) , 2008, Stroke.
[9] S. Yusuf,et al. Challenges of Establishing New Antithrombotic Therapies in Atrial Fibrillation , 2007, Circulation.
[10] J. Eikelboom,et al. A replacement for warfarin: the search continues. , 2007, Circulation.
[11] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[12] R. Tieleman,et al. Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in The Netherlands – The EXAMINE‐AF study. A questionnaire survey , 2007, International journal of clinical practice.
[13] E. Aliot,et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. , 2006, European heart journal.
[14] M. Pfeffer,et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial , 2006, The Lancet.
[15] B. Gage,et al. Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation , 2006, Stroke.
[16] M. Josephson,et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. , 2006, The American journal of cardiology.
[17] Dietrich Andresen,et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. , 2005, European heart journal.
[18] D. Levy,et al. Lifetime Risk for Development of Atrial Fibrillation: The Framingham Heart Study , 2004, Circulation.
[19] Carl van Walraven,et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. , 2002, JAMA.
[20] F. McAlister,et al. Why do patients with atrial fibrillation not receive warfarin? , 2000, Archives of internal medicine.
[21] D. Singer,et al. Warfarin Use among Ambulatory Patients with Nonvalvular Atrial Fibrillation: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 1999, Annals of Internal Medicine.
[22] O. Benavente,et al. Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation , 1999, Annals of Internal Medicine.
[23] S. Lévy,et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. , 1999, Circulation.
[24] D. Singer,et al. Recent national patterns of warfarin use in atrial fibrillation. , 1998, Circulation.
[25] S. Kemp,et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. , 1996, Archives of internal medicine.
[26] P. Wolf,et al. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. , 1987, Archives of internal medicine.
[27] Silvia G. Priori,et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on practice guidelines and the European society of cardiology committee for PRAC , 2006 .